GlassScriptPhysician profile
Thomas Barry Calvit
NPI 1427031731
$763.94
in general payments reported to CMS, 2019-2025
16 companies · $95.94 in 2025
The $95.94 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.60 · 2020: $33.27 · 2021: $81.89 · 2022: $264 · 2023: $128 · 2024: $60.97 · 2025: $95.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.94 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $154.73 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $91.19 | 2022-2025 | Ocaliva |
| Celgene Corporation | $89.99 | 2022-2023 | Zeposia |
| Boston Scientific Corporation | $73.73 | 2019 | |
| Merck Sharp & Dohme LLC | $64.01 | 2022-2024 | Dificid |
| Janssen Biotech, INC. | $60.99 | 2023 | Stelara |
| Genzyme Corporation | $58.17 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.83 | 2020-2021 | |
| Vifor Pharma, INC. | $30.32 | 2022 | |
| Daiichi Sankyo INC. | $18.93 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.96 | 2020 | |
| Medtronic USA, INC. | $14.44 | 2019 | |
| Celltrion USA INC. | $14.44 | 2024 | Vegzelma |
| Abbvie INC. | $12.34 | 2021 | |
| Allergan, INC. | $11.43 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $8.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Calvit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.